Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 84; číslo 3; s. 471 - 485
Hlavní autoři:	Madsen, Marie Lindhard, Due, Hanne, Ejskjær, Niels, Jensen, Paw, Madsen, Jakob, Dybkær, Karen
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2019 Springer Nature B.V
Témata:	Antineoplastic Agents, Phytogenic - adverse effects Autonomic nervous system Blood cancer Cancer Research Central nervous system Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Fluconazole Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Humans Itraconazole Medicine Medicine & Public Health Neurotoxicity Neurotoxicity Syndromes - etiology Neurotoxicity Syndromes - pathology Oncology Peripheral neuropathy Pharmacodynamics Pharmacokinetics Pharmacology/Toxicology Prognosis Quality of life Review Review Article Reviews Vincristine Vincristine - adverse effects Voriconazole Biomarkers Vincristine-induced neuropathy Neurotoxicity Hematologic malignancies Vincristine
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral sensory and motor nerves, autonomic nervous functions, and the central nervous system. This dose-limiting side-effect can diminish quality of life and, furthermore, cause discontinuation of vincristine treatment. The present review elucidates the current knowledge regarding vincristine-induced neuropathy in hematologic malignancies, focusing on neuropathy assessment, clinical and molecular predictive markers, drug–drug interference, prevention, and treatment. Methods This review is conducted by a systematic search strategy for the identification of relevant literature in the PubMed and Embase databases. Results No clinical parameters displayed convincing potential as predictors of vincristine-induced neuropathy; however, preexisting neuropathy was consistently reported to be associated with an increased risk of neurotoxicity. In contrast, molecular markers, including polymorphisms in genes involved in the pharmacodynamics and pharmacokinetics of vincristine, displayed great potential as predictive markers of neuropathy incidence and severity. Furthermore, antifungal drugs, such as itraconazole and voriconazole, decrease the metabolism of vincristine and consequently lead to severe neuropathy when co-administered with vincristine, underscoring why fluconazole should be the antifungal drug of choice. Conclusion Reports from the 71 included studies clearly emphasize the lack of consistency in neuropathy assessment, grading systems, and reporting, making it difficult to interpret results between studies. Thus, truer clinical and molecular markers could emerge if the consistency of neuropathy detection and reporting increases by the use of conventional standardized neuropathy assessment tools and grading scales.
Bibliografie:	ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0344-5704 1432-0843 1432-0843
DOI:	10.1007/s00280-019-03884-5